Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 variants via multiplex assay

The SARS-CoV-2 receptor binding domain (RBD) is both the principal target of neutralizing antibodies and one of the most rapidly evolving domains, which can result in the emergence of immune escape mutations, limiting the effectiveness of vaccines and antibody therapeutics. To facilitate surveillanc...

Descripción completa

Detalles Bibliográficos
Autores principales: Lopez, Ester, Haycroft, Ebene R., Adair, Amy, Mordant, Francesca L., O’Neill, Matthew T., Pymm, Phillip, Redmond, Samuel J., Lee, Wen Shi, Gherardin, Nicholas A., Wheatley, Adam K., Juno, Jennifer A., Selva, Kevin J., Davis, Samantha K., Grimley, Samantha L., Harty, Leigh, Purcell, Damian F.J., Subbarao, Kanta, Godfrey, Dale I., Kent, Stephen J., Tham, Wai-Hong, Chung, Amy W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2021
Materias:
Resource and Technical Advance
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8409985/
https://www.ncbi.nlm.nih.gov/pubmed/34251356
http://dx.doi.org/10.1172/jci.insight.150012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8409985/
https://www.ncbi.nlm.nih.gov/pubmed/34251356
http://dx.doi.org/10.1172/jci.insight.150012

Ejemplares similares